Lattice Biologics Ltd. (LBLTF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Lattice Biologics Ltd. (LBLTF) with AI Score 51/100 (Hold). Lattice Biologics Ltd. develops, manufactures, and markets biologic products for bone regeneration in dental, spine, and orthopedic applications. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 17, 2026Lattice Biologics Ltd. (LBLTF) Healthcare & Pipeline Overview
Lattice Biologics Ltd. is a biotech company specializing in the development and marketing of biologic products for bone regeneration, including amniotic fluid-based products and allografts, primarily serving the dental, spine, and orthopedic markets globally, with a focus on enhancing surgical outcomes.
Investment Thesis
Lattice Biologics Ltd. presents a focused investment opportunity within the bone regeneration market. The company's amniotic fluid-based products, such as AmnioBoost and AmnioBlast, offer potential for growth in the regenerative medicine sector. With a gross margin of 41.4%, the company demonstrates an ability to generate revenue from its products. Key value drivers include the expansion of its product portfolio and penetration into new geographic markets. Upcoming catalysts include potential regulatory approvals for its amniotic fluid-based products and strategic partnerships to expand distribution channels. Potential risks include the company's negative profit margin of -60.2% and reliance on the OTC market for trading, which may impact liquidity and valuation.
Based on FMP financials and quantitative analysis
Key Highlights
- Gross Margin of 41.4% indicates the company's ability to generate revenue from its products.
- Negative Profit Margin of -60.2% reflects ongoing challenges in achieving profitability.
- Beta of 1.21 suggests the stock is more volatile than the overall market.
- The company's focus on bone regeneration addresses a growing need in the dental, spine, and orthopedic markets.
- Lattice Biologics' amniotic fluid-based products offer potential for growth in the regenerative medicine sector.
Competitors & Peers
Strengths
- Proprietary amniotic fluid-based product technology.
- Focus on bone regeneration in specific surgical applications.
- Established relationships with surgeons and hospitals.
- Comprehensive portfolio of allograft options.
Weaknesses
- Negative profit margin.
- Reliance on OTC market for trading.
- Limited market share compared to larger competitors.
- Dependence on regulatory approvals for new products.
Catalysts
- Upcoming: Potential regulatory approvals for AmnioBoost and AmnioBlast products.
- Ongoing: Expansion of distribution channels through strategic partnerships.
- Ongoing: Clinical trials and research demonstrating product efficacy.
- Ongoing: Geographic expansion into new markets.
- Ongoing: Development of new products in related regenerative medicine areas.
Risks
- Ongoing: Negative profit margin and challenges in achieving profitability.
- Potential: Competition from established medical device companies.
- Potential: Regulatory hurdles and changes in healthcare policies.
- Ongoing: Reliance on OTC market for trading, impacting liquidity and valuation.
- Potential: Product liability claims.
Growth Opportunities
- Expansion of Amniotic Fluid-Based Products: Lattice Biologics can capitalize on the growing demand for regenerative medicine by expanding the applications and market reach of its AmnioBoost and AmnioBlast products. The amniotic fluid market is projected to grow significantly, driven by its regenerative properties and potential in various therapeutic areas. Successful clinical trials and regulatory approvals could drive adoption by surgeons and healthcare providers, leading to increased revenue and market share. Timeline: Ongoing.
- Strategic Partnerships and Distribution Agreements: Forming strategic partnerships with established medical device companies or distributors can significantly expand Lattice Biologics' market access and sales reach. Leveraging existing distribution networks can accelerate product adoption and penetration into new geographic markets. These partnerships can also provide access to additional resources and expertise, enhancing the company's competitive position. Timeline: Ongoing.
- Geographic Expansion: Expanding into new geographic markets, particularly in Europe and Asia-Pacific, represents a significant growth opportunity for Lattice Biologics. These regions have a growing demand for advanced bone regeneration products. Adapting products to meet local regulatory requirements and establishing distribution channels in these markets can drive revenue growth and diversification. Timeline: 2-3 years.
- Product Portfolio Diversification: Diversifying the product portfolio beyond bone regeneration to include other regenerative medicine applications, such as wound healing and soft tissue repair, can expand Lattice Biologics' addressable market. Developing and launching new products in these areas can leverage the company's expertise in amniotic fluid-based technologies and address unmet clinical needs. Timeline: 3-5 years.
- Clinical Trials and Research: Investing in clinical trials and research to demonstrate the efficacy and safety of its products can enhance Lattice Biologics' credibility and market acceptance. Positive clinical data can support regulatory approvals and drive adoption by surgeons and healthcare providers. Collaborating with leading research institutions and publishing scientific studies can further strengthen the company's reputation and competitive advantage. Timeline: Ongoing.
Opportunities
- Expansion of amniotic fluid-based product applications.
- Strategic partnerships and distribution agreements.
- Geographic expansion into new markets.
- Product portfolio diversification into related regenerative medicine areas.
Threats
- Competition from established medical device companies.
- Regulatory hurdles and changes in healthcare policies.
- Potential product liability claims.
- Economic downturns affecting healthcare spending.
Competitive Advantages
- Proprietary amniotic fluid-based product technology.
- Established relationships with surgeons and hospitals.
- Focus on bone regeneration in specific surgical applications.
About LBLTF
Lattice Biologics Ltd., headquartered in Belgrade, Montana, is a biotech company focused on developing, manufacturing, and marketing biologic solutions for bone regeneration. The company's products are utilized in a variety of surgical applications across dental, spine, and general orthopedic fields. Lattice Biologics develops novel amniotic fluid-based products, including AmnioBoost and AmnioBlast, alongside a comprehensive portfolio of traditional allografts. These allografts encompass spinal, particulate, soft tissue, dental, membrane and barrier, and demineralized bone matrix options. The company's products are designed to enhance fusion in spine surgery, aid in breast reconstruction post-mastectomy, promote bone regeneration in foot and ankle procedures, and facilitate skull healing after neurosurgery. They also support wound repair in burn victims, hernia repair, and subchondral bone defect repair in knee and other joint surgeries, as well as address sports medicine indications, such as anterior and posterior cruciate ligament repair. Lattice Biologics aims to provide innovative and effective solutions for bone regeneration, addressing unmet needs in the surgical landscape.
What They Do
- Develops biologic products for bone regeneration.
- Manufactures allografts for dental, spine, and orthopedic applications.
- Markets products globally to healthcare providers and hospitals.
- Offers amniotic fluid-based products like AmnioBoost and AmnioBlast.
- Provides traditional allografts, including spinal, particulate, and soft tissue options.
- Addresses a range of surgical applications, including spine fusion and bone regeneration.
Business Model
- Develops and manufactures biologic products for bone regeneration.
- Markets and sells these products to hospitals, surgeons, and other healthcare providers.
- Generates revenue through direct sales and distribution agreements.
Industry Context
Lattice Biologics operates within the medical devices industry, specifically focusing on bone regeneration. The industry is characterized by increasing demand for minimally invasive surgical techniques and regenerative medicine solutions. The competitive landscape includes companies offering allografts and synthetic bone substitutes. Lattice Biologics differentiates itself through its amniotic fluid-based products. The global bone graft and substitutes market is projected to reach billions of dollars by 2026, driven by an aging population and increasing incidence of orthopedic disorders.
Key Customers
- Hospitals and surgical centers
- Orthopedic surgeons
- Dental surgeons
- Spine surgeons
Financials
Chart & Info
Lattice Biologics Ltd. (LBLTF) stock price: Price data unavailable
Latest News
No recent news available for LBLTF.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for LBLTF.
Price Targets
Wall Street price target analysis for LBLTF.
MoonshotScore
What does this score mean?
The MoonshotScore rates LBLTF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Donna Medina
CEO
Donna Medina serves as the CEO of Lattice Biologics Ltd. Her background includes extensive experience in the biotechnology and medical device industries. She has held leadership positions in various companies, focusing on strategic planning, product development, and commercialization. Her expertise spans across regenerative medicine, orthopedics, and surgical solutions. She has a proven track record of driving growth and innovation in the healthcare sector.
Track Record: Under Donna Medina's leadership, Lattice Biologics has focused on expanding its product portfolio and market reach. Key milestones include the development and launch of novel amniotic fluid-based products and strategic partnerships to enhance distribution. She has also overseen efforts to strengthen the company's regulatory compliance and quality control processes. Her strategic decisions have aimed to position Lattice Biologics as a key player in the bone regeneration market.
LBLTF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Lattice Biologics may not meet the minimum financial or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial reporting, making it more difficult for investors to assess their financial health and operational performance. Trading on the OTC Other tier typically involves higher risks compared to exchanges like NYSE or NASDAQ due to less stringent listing standards and regulatory oversight.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and transparency.
- Low trading volume and liquidity.
- Higher price volatility.
- Potential for fraud or manipulation.
- Less stringent regulatory oversight compared to listed exchanges.
- Verify the company's financial statements and SEC filings (if any).
- Assess the company's management team and their track record.
- Evaluate the company's business model and competitive landscape.
- Review the company's legal and regulatory compliance.
- Analyze the company's capital structure and funding sources.
- Monitor news and press releases for any red flags.
- Consult with a qualified financial advisor.
- The company develops and markets biologic products for bone regeneration.
- The company has a CEO and management team in place.
- The company has a portfolio of products, including amniotic fluid-based products and allografts.
- The company's products are used in a range of surgical applications.
- The company is headquartered in Belgrade, Montana.
Common Questions About LBLTF
What does Lattice Biologics Ltd. do?
Lattice Biologics Ltd. is a biotech company that develops, manufactures, and markets biologic products focused on bone regeneration. Their portfolio includes amniotic fluid-based products like AmnioBoost and AmnioBlast, as well as traditional allografts used in dental, spine, and orthopedic surgeries. The company aims to provide innovative solutions for enhancing bone fusion, wound repair, and tissue regeneration in various clinical applications, serving hospitals and surgeons globally.
What do analysts say about LBLTF stock?
As of March 17, 2026, there is no readily available analyst consensus on LBLTF stock due to its listing on the OTC market and limited coverage. Key valuation metrics such as price-to-earnings ratio (-0.01) and profit margin (-60.2%) indicate financial challenges. Growth considerations include the potential for revenue expansion through new product launches and strategic partnerships. Investors should conduct thorough due diligence and consider the risks associated with OTC-listed companies before making investment decisions.
What are the main risks for LBLTF?
The main risks for Lattice Biologics Ltd. include its negative profit margin, indicating ongoing financial challenges. The company's reliance on the OTC market for trading exposes it to liquidity risks and higher price volatility. Competition from larger, established medical device companies poses a threat to market share. Regulatory hurdles and potential product liability claims also represent significant risks. Investors should carefully consider these factors before investing in LBLTF.
What are the key factors to evaluate for LBLTF?
Lattice Biologics Ltd. (LBLTF) currently holds an AI score of 51/100, indicating moderate score. Key strength: Proprietary amniotic fluid-based product technology.. Primary risk to monitor: Ongoing: Negative profit margin and challenges in achieving profitability.. This is not financial advice.
How frequently does LBLTF data refresh on this page?
LBLTF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven LBLTF's recent stock price performance?
Recent price movement in Lattice Biologics Ltd. (LBLTF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary amniotic fluid-based product technology.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider LBLTF overvalued or undervalued right now?
Determining whether Lattice Biologics Ltd. (LBLTF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying LBLTF?
Before investing in Lattice Biologics Ltd. (LBLTF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- OTC market data may be limited and less reliable than exchange-listed data.